Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.68 |
| ▸ | KDR | P35968 | 7/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | BMX | P51813 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117643 | 1.00 | EGFR (0.76) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL5124447 | 0.99 | EGFR (0.77) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL4967379 | 0.92 | EGFR (0.73) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL5117667 | 0.92 | EGFR (0.73) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL5112328 | 0.92 | EGFR (0.73) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL5108714 | 0.90 | EGFR (0.65) | EGFRERBB2KDRSRCERBB4 | |
| SCHEMBL5113512 | 0.90 | EGFR (0.65) | EGFRERBB2KDRSRCERBB4 | |
| SCHEMBL5122522 | 0.89 | EGFR (0.66) | EGFRERBB2KDRSRCERBB4 | |
| SCHEMBL5115923 | 0.88 | EGFR (0.61) | EGFRERBB2KDRERBB4 | |
| SCHEMBL5112366 | 0.87 | EGFR (0.64) | EGFRERBB2KDRSRCERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | EGFR 1/4885ERBB2 3/4885KDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.